Vaccines-2013 - OMICS Group

Recommendations

Info

Yu Qi et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAPathological observation of DNA vaccines on mice infected with multi-drug-resistantMycobacterium tuberculosisYu Qi, Bai Xuejuan and LiningThe 309 th Hospital, P. R ChinaObjective: By observing the histopathological changes in lung, liver and spleen of mice, to study the therapeutic effects of DNAvaccines (HSP60 DNA, Ag85A DNA, Ag85A DNA combined with rifampin, chimeric Ag85A/ESAT-6, chimeric Ag85A/ESAT-6combined with rifampin) in the mouse model of multi-drug resistant (MDR) Mycobacterium tuberculosis infection.Methods: Pathogen-free female B/C mice of 6-8 weeks of age were purchased 80 BALB/c mice were infected with strain HB361by intratail-vein injection HB361,which was resistant to high level of RFP, and low level of isoniazid (INH), and then were dividedinto 8 groups. After 3 days, the mice were treated by saline, vector Pvax1, rifampin, HSP60 DNA, Ag85A DNA, Ag85A DNAcombined with rifampin, chimeric Ag85A/ESAT-6, chimeric Ag85A/ESAT-6, combined with rifampin for 60 days, respectively.The mice were killed after 3 weeks’ treatment. We observed the lung, liver and spleen pathological changes and counted theresidual TB in spleen by acid-fast staining.Results: The Pathological condition of lung, liver and spleen in mice treated by DNA vaccine were better than the control groups,especially the Ag85A DNA groups and Ag85A DNA combined with rifampin group. Also the residual TB of the Ag85A DNAgroups and Ag85A DNA combined with rifampin group were least in spleen.Conclusions: We can evaluate the therapeutic effects of DNA vaccine objectively and accurately according to the histopathologicalchanges in lung, liver and spleen. And the results show that Ag85A DNA vaccine could be an effective agent to therapy the mouseinfected by MDR-TB.BiographyYu Qi has completed her M.D. at the age of 27 years from Medical School of Chongqing University. She is the associate senior doctor. She haspublished more than 15 papers in academic journal.2006njc@sohu.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 124
Hassen Mamo, J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAAntibodies by non-febrile, smear-negative individuals from a malaria epidemic setting inEthiopia are reactive to Plasmodium falciparum blood-stage-vaccine candidate antigensHassen MamoAddis Ababa University, EthiopiaPlasmodium falciparum malaria remains a major public health concern globally though there is some decline in the number ofclinical cases and deaths due to scaling up of control efforts in recent times. Evaluation of the anti-malarial immune profile, inpopulations residing in epidemic-prone areas in the dry season or at the time when vector control largely reduced man-mosquitocontact, would help understand the duration of immune reactivity. A cross-sectional study was designed to investigate antibodyresponses to four P. falciparum blood-stage-vaccine candidate antigens in non-febrile individuals from Shewa Robit in northcentral Ethiopia where malaria transmission was at a minimal level as a result of the sampling season and effective vector control.Blood samples were analyzed microscopically for Plasmodium detection. The enzyme-linked immunosorbent assay (ELISA)was used to measure immunoglobulin (Ig) G (IgG) antibodies to apical membrane antigen 1 (AMA1), glutamate-rich protein(GLURP) R2 region and merozoite surface protein 2 (MSP2) allelic variants (3D7 & FC27). Study participants were smearnegativefor malaria. The antigens tested were well-recognized by the test sera although significant differences were observedin antibody prevalence and level between the different antigens and there was inter-individual variability. There was no serumsample that was not antibody positive against at least one antigen. IgG response to the antigens showed age-related pattern. Thedata suggests that individuals in an unstable and epidemic-prone malaria setting have reactive antibodies that readily recognizeP. falciparum blood-stage vaccine candidate antigens in the absence of slide-positivity.Keywords: Plasmodium falciparum, malaria, immunoglobulin, ELISA, Ethiopia, vaccine, antigen.binmamo@yahoo.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 125
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62:
Track 44: Vaccines against Infectio
Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68:
Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70:
Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72:
Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96: 111 th OMICS Group Conference3 rd I
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123: Aleksandar Masic et al., J Vaccines
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
Page 157 and 158: Veronica Rainone et al., J Vaccines
Page 159 and 160: Page 159
Page 161 and 162: Previous111 th OMICS Group Conferen
Page 163 and 164: PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?